Physician profile
Vada Rose
NPI 1063523454
$2,196.90
in general payments reported to CMS, 2019-2025
21 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $762 · 2023: $287 · 2024: $399 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $308.27 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $292.88 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $165.35 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $150.73 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $138.47 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $129.99 | 2021-2023 | Breztri |
| Janssen Pharmaceuticals, INC | $126.85 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $126.77 | 2022-2024 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $105.42 | 2021 | |
| Lilly USA, LLC | $103.12 | 2021-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $100.16 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $79.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.22 | 2022-2024 | |
| Axsome Therapeutics, INC. | $56.83 | 2024-2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $48.49 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $47.12 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.21 | 2021 | |
| Abbvie INC. | $12.48 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vada Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.